<?xml version="1.0" encoding="UTF-8"?>
<p id="p0130">There is still no complete validation of the inhibitory effect of non-immunosuppressive cyclophilin inhibitors and therapies on coronaviruses, especially COVID-19. However, as a highly promising class of drugs, non-immunosuppressive CyPA inhibitors will attract more attention.</p>
